AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16443229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14519799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal infusion of acetate (60 mmol/L), propionate (20 mmol/L), and butyrate (20 mmol/L)
Number of subjects: 10
Study 14519799 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA infused alone
Number of subjects: 10
Study 14519799 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate-containing infusions
Number of subjects: 10
Study 14519799 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of three SCFA
Number of subjects: 10
Study 11097191 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment readiness training
Number of subjects: 500
Study 11097191 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 500
Study 8630663 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200‐kJ/d diet
Number of subjects: 121
Study 8630663 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200‐kJ/d diet with combined aerobic and anaerobic exercise
Number of subjects: 121
Study 8630663 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 1417159 — intervention group
Group type: EXPERIMENTAL
Intervention: two annual doses of ivermectin 100 mcg/kg
Number of subjects: 58
Study 1417159 — intervention group
Group type: EXPERIMENTAL
Intervention: three semi‐annual doses of ivermectin 100 mcg/kg
Number of subjects: 58
Study 1417159 — intervention group
Group type: EXPERIMENTAL
Intervention: two annual doses of diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58
Study 1417159 — intervention group
Group type: EXPERIMENTAL
Intervention: three semi‐annual doses of diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58
Study 1417159 — intervention group
Group type: EXPERIMENTAL
Intervention: two annual doses of diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 58
Study 4074419 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg bencyclane intravenously
Number of subjects: 4
Study 4074419 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg bencyclane intravenously
Number of subjects: 4
Study 4074419 — intervention group
Group type: EXPERIMENTAL
Intervention: 71 mg bencyclane orally as a solution in water
Number of subjects: 4
Study 4074419 — intervention group
Group type: EXPERIMENTAL
Intervention: 143 mg bencyclane orally as a solution in water
Number of subjects: 4
Study 4074419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bencyclane
Number of subjects: 4
Study 30890289 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear transducer
Number of subjects: 3
Study 30890289 — intervention group
Group type: COMPARATOR
Intervention: Curvilinear transducer
Number of subjects: 3
Study 30291376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy
Number of subjects: 745
Study 30291376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 30291376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-inflammatory subphenotype
Number of subjects: 745
Study 27638496 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92
Study 27638496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 25149143 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic sympathetic block (TSB)
Number of subjects: 36
Study 25149143 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 36
Study 25149143 — intervention group
Group type: EXPERIMENTAL
Intervention: TSB
Number of subjects: 36
Study 22624697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (NOOM)
Number of subjects: 240
Study 22624697 — intervention group
Group type: COMPARATOR
Intervention: Oxygen only (Control)
Number of subjects: 240
Study 20722555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 112
Study 20722555 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 112
Study 20722555 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 112
Study 18408611 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-5 (5 mg.kg(‐1))
Number of subjects: 40
Study 18408611 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-3 (3 mg.kg(‐1))
Number of subjects: 40
Study 18408611 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-1 (1 mg.kg(‐1))
Number of subjects: 40
Study 18408611 — intervention group
Group type: COMPARATOR
Intervention: PL (placebo)
Number of subjects: 40
Study 15737666 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 4
Study 12929288 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (PCI)
Number of subjects: 1205
Study 12929288 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1205
Study 10830413 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa and bromocriptine
Number of subjects: 31
Study 8433469 — intervention group
Group type: EXPERIMENTAL
Intervention: Air suspension bed
Number of subjects: 100
Study 8433469 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU bed
Number of subjects: 100
Study 2890423 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 91 296 and ZK 95 962 (high doses, intravenous)
Number of subjects: 0
Study 2890423 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 95 962
Number of subjects: 0
Study 2890423 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93 426
Number of subjects: 0
Study 2890423 — intervention group
Group type: COMPARATOR
Intervention: ZK 93 426 alone
Number of subjects: 0
Study 2890423 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93 426 in combination with lormetazepam
Number of subjects: 0
Study 28084119 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA)
Number of subjects: 22
Study 28084119 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 27288603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry
Number of subjects: 30
Study 26350611 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intermittent training (HIIT) for 12 weeks
Number of subjects: 28
Study 26350611 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 12 weeks
Number of subjects: 28
Study 23569138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet with keto acid supplementation (0.1 g/kg IBW per day)
Number of subjects: 17
Study 23569138 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet without keto acid supplementation
Number of subjects: 17
Study 22173365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner support (intervention group)
Number of subjects: 788
Study 22173365 — intervention group
Group type: COMPARATOR
Intervention: Physician care (control group)
Number of subjects: 788
Study 19214941 — intervention group
Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg
Number of subjects: 47
Study 19214941 — intervention group
Group type: EXPERIMENTAL
Intervention: BGP-15 400 mg
Number of subjects: 47
Study 19214941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (P) at 20 g/mm²
Number of subjects: 48
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (P) at 40 g/mm²
Number of subjects: 48
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 20 g/mm²
Number of subjects: 48
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 40 g/mm²
Number of subjects: 48
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem (M) at 20 g/mm²
Number of subjects: 48
Study 17080881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem (M) at 40 g/mm²
Number of subjects: 48
Study 14732723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (<2 kg)
Number of subjects: 168
Study 14732723 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal birth weight)
Number of subjects: 168
Study 14732723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (per kg)
Number of subjects: 168
Study 11712625 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (specific dosage not mentioned)
Number of subjects: 0
Study 11712625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10487593 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan 0.5 mg/kg
Number of subjects: 1249
Study 10487593 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan 1.0 mg/kg
Number of subjects: 1249
Study 10487593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1249
Study 10487593 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan (both dosages combined)
Number of subjects: 1249
Study 10487593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncolorectal stratum)
Number of subjects: 1249
Study 10487593 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan (combined groups)
Number of subjects: 1249
Study 7639438 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it)
Number of subjects: 99
Study 7639438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 2654788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of recombinant interferon (rIFN) alpha‐2 and chemotherapy
Number of subjects: 52
Study 2654788 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (VMCP)
Number of subjects: 52
Study 19205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin (1.6 g daily)
Number of subjects: 37
Study 19205 — intervention group
Group type: COMPARATOR
Intervention: Alclofenac (4 g daily)
Number of subjects: 37
Study 19205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tolmetin and Alclofenac
Number of subjects: 37
Study 19205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin and Alclofenac
Number of subjects: 37
Study 31064847 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1413 bispecific T-cell-engaging antibody (bTCE)
Number of subjects: 0
Study 27770480 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative somatosensory testing (QualST)
Number of subjects: 45
Study 27770480 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin application
Number of subjects: 45
Study 27770480 — intervention group
Group type: EXPERIMENTAL
Intervention: QualST in AO patients
Number of subjects: 45
Study 25933402 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-off group (29 eyes)
Number of subjects: 59
Study 25933402 — intervention group
Group type: COMPARATOR
Intervention: DM-on group (30 eyes)
Number of subjects: 59
Study 23822797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25 μg/day as cholecalciferol tablets)
Number of subjects: 77
Study 23822797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21219433 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of rapid-acting insulin (mean 7.3±0.2 units)
Number of subjects: 7
Study 21219433 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% dose of rapid-acting insulin (mean 5.4±0.1 units)
Number of subjects: 7
Study 21219433 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dose of rapid-acting insulin (mean 3.7±0.1 units)
Number of subjects: 7
Study 21219433 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dose of rapid-acting insulin (mean 1.8±0.1 units)
Number of subjects: 7
Study 19968379 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM online cognitive behavioral therapy program
Number of subjects: 1477
Study 19968379 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 1477
Study 17010221 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg G115
Number of subjects: 57
Study 17010221 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg G115
Number of subjects: 57
Study 17010221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg ginseng and 30 mg saccharin)
Number of subjects: 57
Study 17010221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (200 mg ginseng and 30 mg saccharin)
Number of subjects: 57
Study 17010221 — intervention group
Group type: COMPARATOR
Intervention: Placebo-glucose (0 mg ginseng and 25 g oral glucose)
Number of subjects: 57
Study 17010221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng-glucose (200 mg ginseng and 25 g oral glucose)
Number of subjects: 57
Study 17010221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 17010221 — intervention group
Group type: EXPERIMENTAL
Intervention: G115
Number of subjects: 57
Study 15463873 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (Immunocal, 10 g twice a day)
Number of subjects: 21
Study 15463873 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 21
Study 10703903 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 68
Study 10703903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9515415 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zilactin formula (benzyl alcohol)
Number of subjects: 10
Study 9515415 — intervention group
Group type: COMPARATOR
Intervention: Old Zilactin formula (tannic acid)
Number of subjects: 10
Study 8505766 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder sticker
Number of subjects: 703
Study 8505766 — intervention group
Group type: COMPARATOR
Intervention: Control (no reminder sticker)
Number of subjects: 703
Study 3549844 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplementation
Number of subjects: 101
Study 3549844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 29409143 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg) plus standard therapy
Number of subjects: 268
Study 27026522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Number of subjects: 31
Study 25002832 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 83
Study 25002832 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia plus interscalene block
Number of subjects: 83
Study 22722508 — intervention group
Group type: COMPARATOR
Intervention: Phentermine 45 mg
Number of subjects: 30
Study 22722508 — intervention group
Group type: COMPARATOR
Intervention: Phentermine 90 mg
Number of subjects: 30
Study 22722508 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol 20 mg
Number of subjects: 30
Study 22722508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 4 mg
Number of subjects: 30
Study 22722508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 20 mg
Number of subjects: 30
Study 22722508 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant (various doses)
Number of subjects: 30
Study 22722508 — intervention group
Group type: COMPARATOR
Intervention: Phentermine (various doses)
Number of subjects: 30
Study 19900726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP levels in ischemic patients
Number of subjects: 281
Study 19900726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP ≥180 pg/ml
Number of subjects: 281
Study 18272335 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/d)
Number of subjects: 17
Study 18272335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16288148 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education (2 times per week for 8 weeks) and stretching exercises (5 times a week)
Number of subjects: 63
Study 16288148 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 63
Study 16288148 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 63
Study 14595277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue suspension
Number of subjects: 17
Study 14595277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue advancement
Number of subjects: 17
Study 9883861 — intervention group
Group type: EXPERIMENTAL
Intervention: median‐thenar to ulnar‐thenar latency difference (TTLD)
Number of subjects: 50
Study 9883861 — intervention group
Group type: EXPERIMENTAL
Intervention: median‐thenar to ulnar‐hypothenar latency difference (THLD)
Number of subjects: 50
Study 9883861 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐wave ulnar‐to‐median comparative test (FWLD)
Number of subjects: 50
Study 8683249 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 24 hours before and during chemotherapy (arm +/‐)
Number of subjects: 102
Study 8683249 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF after chemotherapy until day 28 or recovery of PMNs (arm ‐/+)
Number of subjects: 102
Study 8683249 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF before, during, and after chemotherapy (arm +/+)
Number of subjects: 102
Study 8683249 — intervention group
Group type: COMPARATOR
Intervention: No GM‐CSF (arm ‐/‐)
Number of subjects: 102
Study 1906864 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily amikacin (7.5 mg/kg bd) regimen (group A)
Number of subjects: 30
Study 1906864 — intervention group
Group type: COMPARATOR
Intervention: Once-daily amikacin (15 mg/kg) schedule (group B)
Number of subjects: 30
Study 6802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen using simple dietary instructions and laxatives
Number of subjects: 435
Study 6802391 — intervention group
Group type: COMPARATOR
Intervention: Preliminary cleansing enema
Number of subjects: 435
Study 30883050 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Hydrochlorothiazide
Number of subjects: 728
Study 30883050 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Perindopril
Number of subjects: 728
Study 30883050 — intervention group
Group type: COMPARATOR
Intervention: Perindopril plus Hydrochlorothiazide
Number of subjects: 728
Study 29157960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) inactivated seasonal influenza vaccine
Number of subjects: 221
Study 29157960 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) inactivated seasonal influenza vaccine
Number of subjects: 221
Study 26002596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus graded exercise therapy
Number of subjects: 296
Study 26002596 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 296
Study 24374369 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Capacity Evaluation (FCE)
Number of subjects: 225
Study 24374369 — intervention group
Group type: COMPARATOR
Intervention: Functional Interviewing
Number of subjects: 225
Study 21476931 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1, 2, and 3 mg/day
Number of subjects: 182
Study 21476931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 21476931 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 182
Study 19066370 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (400 IU/d of all rac-alpha-tocopheryl acetate)
Number of subjects: 35533
Study 19066370 — intervention group
Group type: COMPARATOR
Intervention: Selenium (200 microg/d from L-selenomethionine)
Number of subjects: 35533
Study 19066370 — intervention group
Group type: COMPARATOR
Intervention: Selenium + Vitamin E
Number of subjects: 35533
Study 19066370 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 35533
Study 17606443 — intervention group
Group type: EXPERIMENTAL
Intervention: Double, intensive treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2 followed by cyclophosphamide 120 mg/kg iv plus total body irradiation 9 Gy and autologous stem cell transplantation)
Number of subjects: 303
Study 17606443 — intervention group
Group type: COMPARATOR
Intervention: Single non‐myeloablative treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2)
Number of subjects: 303
Study 17606443 — intervention group
Group type: EXPERIMENTAL
Intervention: Double, intensive treatment
Number of subjects: 303
Study 17606443 — intervention group
Group type: COMPARATOR
Intervention: Single non‐myeloablative treatment
Number of subjects: 303
Study 15172423 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 104
Study 15172423 — intervention group
Group type: COMPARATOR
Intervention: 5 mg amlodipine
Number of subjects: 104
Study 11393219 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (40 microg in 4 doses i.v. at 12 h intervals)
Number of subjects: 5
Study 11393219 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (40 microg in 4 doses i.v.)
Number of subjects: 5
Study 11393219 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (4 doses of 20 microg i.v.)
Number of subjects: 5
Study 11393219 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (3 doses of 13.3 microg at 6 h interval)
Number of subjects: 5
Study 11393219 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin treatment
Number of subjects: 5
Study 9338668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined filtering surgery
Number of subjects: 43
Study 9338668 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery (phacoemulsification) alone
Number of subjects: 43
Study 7958517 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbed group (N = 53)
Number of subjects: 107
Study 7958517 — intervention group
Group type: COMPARATOR
Intervention: Mattress group (N = 54)
Number of subjects: 107
Study 3608590 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 103
Study 3608590 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 103
Study 30989419 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX)
Number of subjects: 0
Study 30989419 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 29511785 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor skill training (VT)
Number of subjects: 0
Study 29511785 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral slow-paced strength training (SPST)
Number of subjects: 0